Lurbinectedin - PharmaMar

Drug Profile

Lurbinectedin - PharmaMar

Alternative Names: PM-01183; PM-1183; Tryptamicidin; Zepsyre

Latest Information Update: 10 Sep 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator PharmaMar
  • Developer Fundacion Instituto Valenciano de Oncologia; PharmaMar; Swiss Group for Clinical Cancer Research
  • Class 3-ring heterocyclic compounds; Acetates; Alkaloids; Antineoplastics; Carbolines; Dioxolanes; Indoles; Small molecules; Tetrahydroisoquinolines
  • Mechanism of Action RNA polymerase II inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ovarian cancer; Small cell lung cancer
  • New Molecular Entity Yes
  • Available For Licensing Yes - Cancer

Highest Development Phases

  • Phase III Ovarian cancer; Small cell lung cancer
  • Phase II Breast cancer; Mesothelioma; Non-small cell lung cancer; Pancreatic cancer; Sarcoma; Solid tumours
  • No development reported Leukaemia

Most Recent Events

  • 06 Sep 2018 Efficacy data from a phase I/II trial in Solid tumours (Small cell lung cancer cohort) released by PharmaMar
  • 06 Aug 2018 Lurbinectedin - PharmaMar receives Orphan Drug status for Small cell lung cancer in USA
  • 31 Jul 2018 PharmaMar completes enrolment in its phase III ATLANTIS trial for Small-cell lung cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top